3CL Pharma,

[delerious1]

"As a consequence, NLC Pharma has assigned ownership of all relevant intellectual property to majority-owned joint venture 3CL Pharma Ltd. The assignment includes the patent applications for dual mechanism (3CL protease inhibitor and CCR5 antagonist) Phase 2 therapeutic drug candidate Tollovir™, commercial-stage 3CL protease inhibitor immune support supplement Tollovid™, and 3CL protease biomarker test TolloTest™ for SARS-CoV-2 infectivity monitoring and PASC/Long COVID viral persistence assessment (“The IP”)."
Todos Medical Partner NLC Pharma Assigns IP for Tollovir(TM), Tollovid(TM), and TolloTest(TM) into JV 3CL Pharma

https://stockhouse.com/news/press-releases/2022/09/12/todos-medical-partner-nlc-pharma-assigns-ip-for-tollovir-tm-tollovid-tm-and